DKK 728.0
(2.82%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 71.43 Million DKK | 2.93% |
2022 | 69.4 Million DKK | 32.34% |
2021 | 52.44 Million DKK | -10.44% |
2020 | 58.55 Million DKK | 1.5% |
2019 | 57.68 Million DKK | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - DKK | -100.0% |
2024 Q2 | - DKK | 0.0% |
2023 FY | 71.43 Million DKK | 2.93% |
2023 Q3 | 60.68 Million DKK | -18.32% |
2023 Q2 | 74.29 Million DKK | 11.62% |
2023 Q4 | 71.43 Million DKK | 17.71% |
2023 Q1 | 66.56 Million DKK | -4.09% |
2022 Q4 | 69.4 Million DKK | 13.85% |
2022 FY | 69.4 Million DKK | 32.34% |
2022 Q3 | 60.96 Million DKK | 0.0% |
2022 Q1 | - DKK | 0.0% |
2021 FY | 52.44 Million DKK | -10.44% |
2020 FY | 58.55 Million DKK | 1.5% |
2019 FY | 57.68 Million DKK | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
ALK-Abelló A/S | 765 Million DKK | 90.662% |
Bavarian Nordic A/S | 145.3 Million DKK | 50.837% |
Genmab A/S | 770 Million DKK | 90.723% |
Novo Nordisk A/S | 27 Billion DKK | 99.735% |
Orphazyme A/S | - DKK | -Infinity% |
Pharma Equity Group A/S | 30.22 Million DKK | -136.375% |
Zealand Pharma A/S | 200.27 Million DKK | 64.332% |